CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net income	$ 122,320	$ 17,673	$ 60,267
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,350	18,280	19,303
Amortization of debt issuance cost	1,347	473	0
Loss on disposal of property and equipment	91	0	42
Impairment of goodwill and intangible assets	0	1,994	3,799
Provision for doubtful accounts	0	(1,363)	3,888
Share-based compensation	3,383	1,547	1,441
Gain on sale of equity method investment	(99,839)	0	0
Gain on loan assumption	0	(2,250)	0
Unrealized loss (gain) from investment in equity securities	11	(9)	25
(Income) loss from equity method investments	(3,694)	6,901	8,125
Deferred tax	(6,620)	(6,801)	(8,345)
Changes in operating assets and liabilities, net of acquisition amounts:
Receivables, net	4,134	10,714	(263)
Receivables, net – related parties	(1,123)	(1,435)	(28,363)
Other receivables	12,589	(15,079)	0
Prepaid expenses and other current assets	(6,432)	(2,756)	(2,814)
Right-of-use assets	3,325	2,480	0
Other assets	(5,530)	(572)	2
Accounts payable and accrued expenses	8,204	(4,883)	(22,669)
Fiduciary accounts payable	7,615	488	0
Capitation incentives payable	0	0	(21,500)
Medical liabilities	(8,691)	(2,392)	4,134
Income taxes payable	(304)	(7,093)	8,424
Operating lease liabilities	(2,973)	(2,244)	0
Net cash provided by operating activities	46,163	13,673	25,496
Cash flows from investing activities
Purchases of marketable securities	(1,793)	(115,402)	(9)
Proceeds from sale of marketable securities	50,625	0	0
Proceeds from repayment of loans receivable - related parties	16,500	0	0
Advances on loans receivable	(145)	(11,425)	(7,500)
Dividends received from equity method investments	0	240	607
Proceeds from sale of fixed assets	50	0	0
Payments for business acquisitions, net of cash acquired	(11,354)	(49,403)	0
Purchases of investments in privately held entities	0	(491)	(405)
Proceeds from sale of equity method investment	52,743	0	0
Purchases of investments – equity method	(9,969)	(3,108)	(16,706)
Purchases of property and equipment	(1,164)	(1,042)	(1,170)
Net cash provided by (used in) investing activities	95,493	(180,631)	(25,183)
Cash flows from financing activities
Dividends paid	(51,319)	(61,717)	(17,759)
Repayments of debt	0	(2,375)	0
Change in noncontrolling interest capital	0	28	27
Borrowings on long-term debt	0	250,000	8,000
Borrowings on line of credit	0	39,600	0
Repayments on bank loan and lines of credit	0	(52,640)	(495)
Payment of capital lease obligations	(105)	(102)	(99)
Proceeds from exercise of stock options and warrants	10,802	3,123	3,997
Proceeds from common stock offering	0	755	200
Repurchase of common shares	(537)	(7,570)	(5,047)
Distribution to noncontrolling interest	(1,037)	0	0
Cost of debt and equity issuances	0	(5,771)	0
Net cash (used in) provided by financing activities	(51,696)	163,331	(11,176)
Net increase (decrease) in cash, cash equivalents and restricted cash	89,960	(3,627)	(10,863)
Cash, cash equivalents and restricted cash, beginning of year	104,010	107,637	118,500
Cash, cash equivalents and restricted cash, end of year	193,970	104,010	107,637
Supplemental disclosures of cash flow information
Cash paid for income taxes	62,002	20,200	23,643
Cash paid for interest	8,510	4,258	462
Supplemental disclosures of non-cash investing and financing activities
Cashless exercise of warrants	599	0	0
Deferred tax liability adjusted to goodwill	0	6,334	1,110
Reclassification of liability for equity shares	0	1,185	0
Purchase price adjustment for acceleration of vested stock options	0	0	868
Conversion of loan receivable to investment in Accountable Health Care, IPA	0	0	5,000
Reclassification of dividends related to share repurchase	0	0	4,216
Reclassification of APS noncontrolling interest to equity related to purchase of additional shares	0	0	2,832
Deferred tax liability adjustment related to warrant exercises	690	0	0
Preferred shares received from sale of equity method investment	36,179	0	0
Beneficial interest acquired from sale of equity method investment	15,723	0	0
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	193,470	103,189	106,892
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	193,970	107,637	118,500
Affiliated Entity | APC
Supplemental disclosures of non-cash investing and financing activities
APC stock issued in exchange for AMG	0	414	0
Term Loan
Cash flows from financing activities
Repayments of debt	$ (9,500)	$ 0	$ 0